

Nicole Tait

Patient:

TAIT, NICOLE MEGHAN

HC #:

5561276196EA

Phone:

(519) 835-6239

Lab No:

2022-9A6480033

Age:

51 years

DOB:

Oct 28 1970

Date of Service:

Feb 17 2022 08:33

Reported On:

Feb 17 2022 16:13

Gender:

Female

Patient ID:**Referring Site ID:****Reported By:**

LifeLabs

Ordered By:

ALEXOPOULOS DR. K.

CC:**Flags Results Reference Units**

	Hematology		
WBC	4.0	4.0 - 11.0	x E9/L
RBC	4.89	4.00 - 5.10	x E12/L
Hemoglobin	135	120 - 160	g/L
Hematocrit	0.428	0.350 - 0.450	L/L
MCV	88	80 - 100	fL
MCH	27.6	27.5 - 33.0	pg
MCHC	315	305 - 360	g/L
RDW	12.1	11.5 - 14.5	%
Platelet Count	258	150 - 400	x E9/L
Differential			
Neutrophils	LO 1.7	2.0 - 7.5	x E9/L
Lymphocytes	1.8	1.0 - 3.5	x E9/L

Monocytes	0.4	0.2 - 1.0	x E9/L
Eosinophils	0.1	0.0 - 0.5	x E9/L
Basophils	0.0	0.0 - 0.2	x E9/L
Immature Granulocytes	0.0	0.0 - 0.1	x E9/L
Nucleated RBC	0		/100 WBC

Biochemical Investigation of Anemias

Ferritin	50	5-272	ug/L
----------	----	-------	------

General Chemistry

Glucose Random	4.7	3.6 - 7.7	mmol/L
Hemoglobin A1C/Total Hemoglobin	5.4	<6.0	%

Diabetes Canada 2018 Guidelines:

 Screening and Diagnosis: < 5.5 % Normal
 5.5% - 5.9 % At risk
 6.0% - 6.4 % Prediabetes
 >OR= 6.5 % Diabetes Mellitus
 If HbA1c >OR= 6.5 % and asymptomatic, confirm using Fasting Glucose, HbA1c or 75g OGTT.

 Monitoring:

Creatinine	70	50-100	umol/L
Glomerular Filtration Rate (eGFR)	87		

An eGFR from 60-89 ml/min/1.73 m² is consistent with mildly decreased kidney function. However, in the absence of other evidence of kidney disease, eGFR values in this range do not fulfill the KDIGO criteria for chronic kidney disease. Interpret results in concert with ACR measurement. For patients of African descent, the reported eGFR must be multiplied by 1.15. Effective May 4 2015, eGFR is calculated using the CKD-EPI 2009 equation. KDIGO 2012 guidelines highlight the importance of eGFR and urine albumin creatinine ratio (ACR) in screening, diagnosis and management of CKD.

Lipids

Hours After Meal	0	Hours
Triglyceride	0.72	mmol/L
Cholesterol	5.52	mmol/L
HDL Cholesterol	2.38	mmol/L

New formulation (24/Sep/2018): In some patients with abnormal liver function, the HDL-c result may be different due to the presence of lipoproteins with abnormal lipid distribution.

Non HDL Cholesterol	3.14	mmol/L	Non HDL-Cholesterol is not affected by the fasting status of the patient.
LDL Cholesterol (Calculated)	2.81	mmol/L	LDL-C calculation is decreased if fasting < or = 10 hours. Consider the Non HDL-C value as an alternate lipid target if monitoring treatment in intermediate or high risk patients.
Cholesterol/HDL Cholesterol	2.3		Lipid Target Values should be based on patient 10 year CVD risk assessment. ! High or Intermediate CVD risk -----!----- Primary ! LDL-C < or = 2.0 mmol/L OR Tx target ! > or = 50% decrease in LDL-C ! Alternate ! Non HDL-C < or = 2.6 mmol/L OR Tx target ! ApoB < or = 0.8 g/L -----!----- ! Low CVD risk -----!----- Primary !> or = 50% decrease in LDL-C Tx target ! -----!-----
Lipid Target Values			

English

[About Us](#)
[Accessibility](#)
[Privacy Statement](#)
[Terms of Use](#)
[Report A Vulnerability](#)
[Site Map](#)